Role of polymorphisms in BCL-2 and BAX genes in modulating the risk of developing non-Hodgkin lymphoma

References

• Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.
   PubMed Web of Science ®Google Scholar
• Klaunig JE, Kamendulis LM, Hocevar BA. Oxidative stress and oxidative damage in carcinogenesis. Toxicol Pathol 2010;38:96–109.
   PubMed Web of Science ®Google Scholar
• Zenz T, Benner A, Duhrsen U, et al. BCL2–938C> A polymorphism and disease progression in chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:1837–1842.
   PubMed Web of Science ®Google Scholar
• Kelly JL, Novak AJ, Fredericksen ZS, et al. Germline variation in apoptosis pathway genes and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 2010;19:2847–2858.
   PubMed Web of Science ®Google Scholar
• Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007;35:495–516.
   PubMed Web of Science ®Google Scholar
• Mazrouei S, Ziaei A, Tanhaee AP, et al. Apoptosis inhibition or inflammation: the role of NAIP protein expression in Hodgkin and non-Hodgkin lymphomas compared to non-neoplastic lymph node. J Inflamm (Lond) 2012;9:4.
   PubMed Web of Science ®Google Scholar
• Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res 2011;30:87.
   PubMed Web of Science ®Google Scholar
• Willis TG, Dyer MJ. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood 2000;96:808–822.
   PubMed Web of Science ®Google Scholar
• Gu Y, Pan Y, Meng B, et al. High levels of bcl-2 protein expression do not correlate with genetic abnormalities but predict worse prognosis in patients with lymphoblastic lymphoma. Tumour Biol 2013;34:1441–1450.
   PubMed Web of Science ®Google Scholar
• Faderl S, Keating MJ, Do KA, et al. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia 2002;16:1045–1052.
   PubMed Web of Science ®Google Scholar
• Bachmann HS, Heukamp LC, Schmitz KJ, et al. Regulatory BCL2 promoter polymorphism (-938C> A) is associated with adverse outcome in patients with prostate carcinoma. Int J Cancer 2011;129:2390–2399.
   PubMed Web of Science ®Google Scholar
• Aguilar-Santelises M, Rottenberg ME, Lewin N, et al. Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int J Cancer 1996;69:114–119.
   PubMed Web of Science ®Google Scholar
• Pepper C, Hoy T, Bentley DP. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer 1997;76:935–938.
   PubMed Web of Science ®Google Scholar
• Nuckel H, Frey UH, Bau M, et al. Association of a novel regulatory polymorphism (-938C> A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood 2007;109:290–297.
   PubMed Web of Science ®Google Scholar
• Bachmann HS, Otterbach F, Callies R, et al. The AA genotype of the regulatory BCL2 promoter polymorphism (938C> A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients. Clin Cancer Res 2007;13:5790–5797.
   PubMed Web of Science ®Google Scholar
• Chen K, Hu Z, Wang LE, et al. Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck. Carcinogenesis 2007;28:2008–2012.
   PubMed Web of Science ®Google Scholar
• Komaki S, Kohno M, Matsuura N, et al. The polymorphic 43Thr bcl-2 protein confers relative resistance to autoimmunity: an analytical evaluation. Hum Genet 1998;103:435–440.
   PubMed Web of Science ®Google Scholar
• Jain M, Kumar S, Lal P, et al. Role of BCL2 (ala43thr), CCND1 (G870A) and FAS (A-670G) polymorphisms in modulating the risk of developing esophageal cancer. Cancer Detect Prev 2007;31: 225–232.
   PubMedGoogle Scholar
• Fegan C, Starczynski J, Pratt G, Pepper C. The role of the bax gene polymorphism G(-248)A in chronic lymphocytic leukemia. Leukemia 2006;20:1460–1461.
   PubMed Web of Science ®Google Scholar
• Jaffe ES, Harris NL, Stein H, et al., editors. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2001.
   Google Scholar
• Fujimura H, Kawasaki T, Sakata T, et al. Common C677T polymorphism in the methylenetetrahydrofolate reductase gene increases the risk for deep vein thrombosis in patients with predisposition of thrombophilia. Thromb Res 2000;98:1–8.
   PubMed Web of Science ®Google Scholar
• Liu Z, Sun R, Lu W, et al. The -938A/A genotype of BCL2 gene is associated with esophageal cancer. Med Oncol 2012;29:2677–2683.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Kepp O, Trojel-Hansen C, et al. Non-apoptotic functions of apoptosis-regulatory proteins. EMBO Rep 2012;13:322–330.
   PubMed Web of Science ®Google Scholar
• Park BL, Kim LH, Cheong HS, et al. Identification of variants in cyclin D1 (CCND1) and B-cell CLL/lymphoma 2 (BCL2). J Hum Genet 2004;49:449–454.
   PubMed Web of Science ®Google Scholar
• Young RL, Korsmeyer SJ. A negative regulatory element in the bcl-2 5’-untranslated region inhibits expression from an upstream promoter. Mol Cell Biol 1993;13:3686–3697.
   PubMed Web of Science ®Google Scholar
• Luscher B, Eisenman RN. New light on Myc and Myb. Part II. Myb. Genes Dev 1990;4:2235–2241.
   PubMed Web of Science ®Google Scholar
• Saxena A, Moshynska O, Sankaran K, et al. Association of a novel single nucleotide polymorphism, G(-248)A, in the 5’-UTR of BAX gene in chronic lymphocytic leukemia with disease progression and treatment resistance. Cancer Lett 2002;187:199–205.
   PubMed Web of Science ®Google Scholar
• Starczynski J, Pepper C, Pratt G, et al. Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic leukemia once treatment is initiated. J Clin Oncol 2005;23:1514–1521.
   PubMed Web of Science ®Google Scholar
• Zhang L, Yu J, Park BH, et al. Role of BAX in the apoptotic response to anticancer agents. Science 2000;290:989–992.
   PubMed Web of Science ®Google Scholar
• Bellosillo B, Villamor N, Lopez-Guillermo A, et al. Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia. Blood 2002;100:1810–1816.
   PubMed Web of Science ®Google Scholar
• Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293–299.
   PubMed Web of Science ®Google Scholar
• Mitchell KO, Ricci MS, Miyashita T, et al. Bax is a transcriptional target and mediator of c-myc-induced apoptosis. Cancer Res 2000;60:6318–6325.
   PubMed Web of Science ®Google Scholar
• Bentires-Alj M, Dejardin E, Viatour P, et al. Inhibition of the NF-kappa B transcription factor increases Bax expression in cancer cell lines. Oncogene 2001;20:2805–2813.
   PubMed Web of Science ®Google Scholar
• Rampino N, Yamamoto H, Ionov Y, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997;275:967–969.
   PubMed Web of Science ®Google Scholar
• Meijerink JP, Mensink EJ, Wang K, et al. Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood 1998;91:2991–2997.
   PubMed Web of Science ®Google Scholar
• Zhang N, Li X, Tao K, et al. BCL-2 (-938C > A) polymorphism is associated with breast cancer susceptibility. BMC Med Genet 2011;12:48.
   PubMed Web of Science ®Google Scholar
• Wang YX, Zhao L, Wang XY, et al. Role of Caspase 8, Caspase 9 and Bcl-2 polymorphisms in papillary thyroid carcinoma risk in Han Chinese population. Med Oncol 2012;29:2445–2451.
   PubMed Web of Science ®Google Scholar